Engineered Probiotic Nanobody Delivery for Oral Mucosal Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current COVID-19 vaccines are primarily administered via intramuscular injections, which pose challenges in distribution and may not induce robust mucosal and systemic immune responses, necessitating a safer and more effective oral vaccine delivery system that stimulates both humoral and cellular immune responses.
Innovation Solution
A genetically modified probiotic bacterium, such as E. coli Nissle 1917, is engineered to surface-display anti-spike glycoprotein nanobodies using Intimin or Lpp-OmpA anchors, allowing for oral delivery and expression of Spike-RBD proteins, which inhibit virus-ACE2 interaction and stimulate immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intramuscular injection is used for vaccine delivery, then neutralizing antibody response against Spike protein is achieved, but distribution bottlenecks occur and patient compliance decreases due to needle fear
Solution Approach 1:
The patent replaces the mechanical injection system (needles, syringes, trained vaccinators) with an oral probiotic delivery system that patients can self-administer. The probiotic bacterium delivers Spike protein antigen through the gastrointestinal tract, eliminating the need for parenteral administration while maintaining immunogenicity.
Solution Approach 2:
The patent introduces a probiotic bacterium as an intermediary carrier to deliver the Spike protein antigen. This probiotic mediator transports the antigen through the GI tract to stimulate immune responses, serving as a bridge between oral administration and systemic immune activation.
2Reliability
If intramuscular injection is used for vaccine delivery, then neutralizing antibody response is achieved, but distribution and manufacturing complexity increases
Solution Approach 1:
The patent replaces the complex injection delivery infrastructure (cold chain, trained personnel, sterile equipment) with a simple oral probiotic formulation that can be manufactured and distributed using conventional pharmaceutical techniques, significantly reducing system complexity.
3Ease of operation
If oral vaccine delivery is used, then patient compliance and ease of administration improve, but robust mucosal and systemic immune responses may not be induced
Solution Approach 1:
The patent uses a composite probiotic system where the probiotic bacterium itself serves as the delivery vehicle and the Spike protein is expressed on or within the bacterial surface. This composite structure ensures the antigen reaches the gastrointestinal immune system effectively, stimulating both mucosal and systemic immune responses through the gut-associated lymphoid tissue.
Solution Approach 2:
The probiotic bacterium acts as an intermediary that not only transports the antigen but also actively stimulates immune responses through its interaction with gut-associated lymphoid tissue, ensuring robust immunogenicity despite oral administration.
4Reliability
If current COVID-19 vaccines are used, then protection is achieved, but duration and breadth of coverage are limited requiring booster doses
Solution Approach 1:
The patent shifts from parenteral delivery (muscle injection) to oral delivery (gastrointestinal tract), accessing a different immunological dimension through the gut-associated lymphoid tissue. This dimensional change enables stimulation of both mucosal and systemic immune responses, potentially achieving broader and longer-lasting protection including cellular immunity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered probiotic induces both mucosal and systemic immunity by generating anti-spike antibodies, inhibiting virus-ACE2 receptor interaction, and providing long-lasting protection against SARS-COV-2, while being suitable for self-administration and cost-effective mass production.
Implementation Method 1
A genetically modified probiotic bacterium, such as E. coli Nissle 1917, is engineered to surface-display anti-spike glycoprotein nanobodies using Intimin or Lpp-OmpA anchors
Implementation Method 2
one or more anti-spike glycoprotein nanobodies on the outer membrane of the bacterium
Implementation Method 3
The engineered probiotic induces both mucosal and systemic immunity by generating anti-spike antibodies
Implementation Method 4
allowing for oral delivery and expression of Spike-RBD proteins
Implementation Method 5
inhibiting virus-ACE2 receptor interaction
Data Source
AI summary
A novel genetically modified bacterium is disclosed. The bacterium has one or more anti-spike glycoprotein nanobodies on the outer membrane of the bacterium. In one embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Intimin. In another embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Lpp-OmpA.